FDA seeks transparent relationship on manufacturing standards

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Jirapong Manustrong)
(Image: Getty/Jirapong Manustrong)

Related tags Fda Transparency CDER

US FDA is reaching out to the industry to agree upon ‘voluntary consensus standards’ to promote the development of drugs and reduce manufacturing cost.

The US Food and Drug Administration (FDA) published new draft guidance entitled the Program for the Recognition of Voluntary Consensus Standards Related to Pharmaceutical Quality​, which will see industry stakeholders and FDA staff mutually agree to pharmaceutical quality standards.

The agency aims for the program to create a list of standards that can be hosted on its website that manufacturers can use as a reference prior to the FDA’s assessment of the quality of its products and its manufacturing processes.

Though the standards will be voluntary and will not change the requirements of the Federal Food, Drug, and Cosmetic Act, the FDA expects the agreed standards to streamline applications that successfully adhere to the points outlined between industry and the regulator.

In the FDA’s overview of the program, it noted that it specifically hopes that this course of action will improve the speed with which generics and biosimilars are manufactured, which should ‘spur competition’ on the market.

The Center for Drug Evaluation and Research (CDER) noted in the draft guidance that the program will “provide transparency to industry and other stakeholders regarding CDER’s thinking about a particular method or approach.”

Will having a mutually agreed set of voluntary manufacturing standards result in a greater number of approvals and fewer manufacturing issues?
Yes, in the short-term, it should make requirements clearer
Yes, in the long-term, it will improve communication between stakeholders
Hard to say until it is launched
No, the program will make little difference
Created with Poll Maker

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...